Aligos Therapeutics (ALGS) Stock Price, News & Analysis

Company Overview

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $7.55 to $8.50
• 50-Day Range: $4.36 to $8.37
• 52-Week Range: $3.76 to $46.80
• Volume: 152,858 shs
• Average Volume: 209,461 shs
• Market Capitalization: $46.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $70.00
• Consensus Rating: Buy

Aligos Therapeutics Stock Analysis - MarketRank™

Aligos Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 616th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aligos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aligos Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aligos Therapeutics are expected to decrease in the coming year, from ($10.36) to ($11.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aligos Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aligos Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.10% of the float of Aligos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aligos Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aligos Therapeutics has recently decreased by 13.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aligos Therapeutics does not currently pay a dividend.

Dividend Growth

Aligos Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.80

Percentage of Shares Shorted

13.10% of the float of Aligos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aligos Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aligos Therapeutics has recently decreased by 13.65%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Aligos Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for ALGS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

1 people have added Aligos Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.80% of the stock of Aligos Therapeutics is held by insiders.

Percentage Held by Institutions

60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALGS Stock Analysis - Frequently Asked Questions

How have ALGS shares performed this year?

Aligos Therapeutics' stock was trading at $39.84 at the beginning of the year. Since then, ALGS shares have decreased by 81.0% and is now trading at $7.55.
View the best growth stocks for 2025 here.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced its earnings results on Tuesday, May, 6th. The company reported ($2.11) earnings per share for the quarter, beating the consensus estimate of ($2.80) by $0.69. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.33 million. Aligos Therapeutics had a negative net margin of 1,628.75% and a positive trailing twelve-month return on equity of 14.67%.

When did Aligos Therapeutics' stock split?

Aligos Therapeutics shares reverse split before market open on Monday, August 19th 2024. The 1-25 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Aligos Therapeutics IPO?

Aligos Therapeutics (ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

Who are Aligos Therapeutics' major shareholders?

Top institutional investors of Aligos Therapeutics include Adage Capital Partners GP L.L.C. (7.61%), Alyeska Investment Group L.P. (6.74%), Woodline Partners LP (5.16%) and Heights Capital Management Inc. (3.95%).
View institutional ownership trends.

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aligos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aligos Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Athenex (ATNX), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM) and Adverum Biotechnologies (ADVM).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 6/20/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALGS
• CIK: 1799448
• Web: www.aligos.com
• Phone: 800-466-6059
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $70.00
• High Stock Price Target: $70.00
• Low Stock Price Target: $70.00
• Potential Upside/Downside: +794.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($17.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$131.21 million
• Net Margins: -1,628.75%
• Pretax Margin: -1,618.04%
• Return on Equity: 14.67%
• Return on Assets: 7.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.56
• Quick Ratio: 7.56

Sales & Book Value

• Annual Sales: $3.94 million
• Price / Sales: 12.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($7.50) per share
• Price / Book: -1.04

Miscellaneous

• Outstanding Shares: 6,110,000
• Free Float: 5,821,000
• Market Cap: $47.84 million
• Optionable: No Data
• Beta: 2.69